PubRank

Dragana Milojkovic

Author PubWeight™ 58.52‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008 5.08
2 Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2011 4.32
3 Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010 4.21
4 European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008 2.90
5 Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood 2013 2.16
6 In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 2007 1.92
7 Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008 1.76
8 PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 2013 1.72
9 Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood 2012 1.64
10 Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011 1.63
11 Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood 2012 1.54
12 Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. Leuk Lymphoma 2013 1.53
13 Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006 1.51
14 Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 2008 1.36
15 Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 2013 1.27
16 Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood 2010 1.26
17 Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 2013 1.21
18 Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood 2013 1.14
19 Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy. Haematologica 2012 1.12
20 Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 2010 1.08
21 Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood 2010 1.08
22 Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood 2007 1.00
23 Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica 2011 1.00
24 Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements. Cancer Genet Cytogenet 2008 0.97
25 BCR-ABL1 kinase domain mutations: methodology and clinical evaluation. Am J Hematol 2012 0.95
26 EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure. Biol Blood Marrow Transplant 2011 0.89
27 EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. Blood 2010 0.87
28 Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood 2013 0.85
29 Managing pregnancy in chronic myeloid leukaemia. Ann Hematol 2015 0.85
30 Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia. Am J Hematol 2009 0.84
31 Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation. Biol Blood Marrow Transplant 2010 0.84
32 Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. Blood 2010 0.83
33 MSQoL-54 predicts change in fatigue after inpatient rehabilitation for people with multiple sclerosis. Disabil Rehabil 2012 0.83
34 The next questions in chronic myeloid leukaemia and their answers. Curr Opin Hematol 2013 0.83
35 Variant isoforms of BCR-ABL1 in chronic myelogenous leukemia reflect alternative splicing of ABL1 in normal tissue - letter. Mol Cancer Ther 2010 0.80
36 A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia. Br J Haematol 2013 0.80
37 Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 2010 0.80
38 Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia. Blood 2007 0.79
39 Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? Br J Haematol 2009 0.79
40 Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. Blood 2012 0.76
41 Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation. Haematologica 2011 0.76
42 The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib. Haematologica 2009 0.76
43 Imatinib and chronic myeloid leukemia: close to the bone. Leuk Lymphoma 2013 0.75
44 Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system. Br J Haematol 2011 0.75
45 Systemic mastocytosis - the importance of looking within bone marrow fragments: AJH Educational Material. Am J Hematol 2014 0.75
46 Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects. Br J Haematol 2013 0.75
47 Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy. Blood 2012 0.75
48 Acquired factor V inhibitor after haematopoietic stem cell transplantation. Thromb Haemost 2007 0.75